SEINE BIO · SCIENCE LIBRARY
Amycretin
Amycretin is a single-molecule GLP-1 and amylin receptor agonist in clinical development.
Research compoundA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Amycretin.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Overview
Amycretin is an investigational molecule designed to activate both GLP-1 and amylin receptors. It is being developed in different formulations, which makes product identity important when reading early weight-management news. Encouraging trial results explain the interest, but they do not establish that a consumer product is approved or available through a clinic.
Community Use
Public discussion often groups Amycretin with established weight-loss medicines because of its overlapping appetite pathways. That comparison can be helpful only when formulation and trial stage remain visible. No exact Amycretin profile was found in the requested community catalogs in this review; we therefore do not present a supplier schedule as a verified community standard.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Initial 0.3 mg weekly; separate target arms 1.25, 5, 20 or 60 mg | Weekly | 1.25 mg arm: 20 weeks; 5 mg arm: 28 weeks; 20/60 mg arms: 36 weeks Break: No biohacking break established by this study | Controlled subcutaneous human study Lancet 2025: amycretin phase 1b/2a |
| Oral | Initial 1.5 mg daily; escalation every 4 weeks toward separate 6, 25 or 50 mg targets | Daily | 36 weeks Break: No biohacking break established by this study | Controlled oral human study Lancet 2026: oral zenagamtide phase 2 |
| Subcutaneous in the chart; oral is discussed as a separate formulation | Injectable chart: 1.25 mg in weeks 1–4, 5 mg in weeks 5–12, 20 mg in weeks 13–20 and 60 mg from week 21 as the highest studied step. | Once weekly for injection; once daily for oral discussion | Chart extends beyond week 21; clinical discussion cites 20–36-week injectable studies, not a single validated cycle. Break: Not stated | Published informal biohacking claim PeptideDosage |
| Subcutaneous injection and separate oral administration | At-a-glance table lists 0.3 mg for injection and 1 mg for oral administration. | Injection weekly; oral daily | 36 weeks for its injectable row; 12 weeks for its oral row Break: Not stated | Published informal biohacking claim Pepwise |
Important context: Route and trial must be identified. Oral and injectable mg amounts cannot be combined into one dose range, and no approved average or safe maximum is established.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The human study below investigated escalating subcutaneous exposures within a controlled protocol. Those study groups are not a consumer cycle, and oral formulations cannot be substituted by matching milligram numbers. A study-duration entry belongs beside its population and route; it should not be read as instructions to start or titrate an unapproved product.
Research Findings
A 2025 phase 1b/2a randomized study included 125 participants with overweight or obesity at one US center. Its multiple parts assessed tolerability, pharmacokinetics, and weight outcomes, with treatment extending up to 36 weeks in a study part. This is human clinical research, unlike a laboratory mechanism experiment. Early-phase subcutaneous trial.
U.S. Approval & Access
Amycretin remains investigational in this evidence review; no FDA-approved Amycretin prescribing label was identified. A trial publication and a manufacturer development announcement are different from marketing authorization. Research participation depends on a genuine study, eligibility, and enrollment decisions made by the study team.
What It Does in the Body
GLP-1 and amylin signaling both participate in eating-related physiology, but through partly different pathways. Amycretin places those activities within one investigational molecule. This does not make it equivalent to separately combining two products, and the scientific design alone cannot tell an individual what their weight response or tolerability will be. Reliable onset, peak clinical benefit, and duration for a proposed retail Amycretin program are not established; trial exposure does not provide a consumer timetable.
Benefits & Reported Experiences
Early weight-loss findings support continued development, not a guarantee of superior results for every patient. Phase, sample size, treatment duration, and participant selection affect how much can be concluded. Comparisons with another drug require an appropriate head-to-head study; separate trial averages are not personalized predictions.
Side Effects & Risks
Tolerability is a central question for a dual appetite-pathway intervention. Symptoms, discontinuations, and serious events must be assessed using the actual trial report and future prescribing information if approved. The absence of a final label means consumer safety advice cannot simply be borrowed from semaglutide or another amylin program.
Delivery Options
The cited trial concerns a subcutaneous formulation. Oral Amycretin development represents a separate delivery approach and may have different exposure characteristics. A research name shared across delivery methods does not permit route switching, vial substitution, or self-directed conversion. This profile does not provide an administration technique.
Product Quality & Storage
For trial evidence, check which formulation was manufactured for the sponsor, which population received it, and how adverse events were monitored. Retail research material lacks that complete chain of clinical evidence. A familiar molecule name does not establish equivalence to the investigational product used by a study team. Storage and handling of sponsor trial material follow the study’s controls. No retail storage directions are inferred for unapproved Amycretin products.
Combinations & Interactions
There is no basis here for a consumer Amycretin stack with GLP-1 medicines, amylin analogs, or research peptides. The fact that a molecule has two targets is not permission to add more appetite drugs. Combination safety and benefit require their own evaluation, particularly when overlapping pathways may complicate tolerability.
Talking With Your Provider
A clinician can review the reason you are interested in Amycretin and compare that goal with established options available now. Bring your medication history and previous weight-management experience. Ask whether an appropriate registered trial exists, while recognizing that enrollment is uncertain and membership does not secure access to an investigational drug.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Metabolic health & weight-management scienceEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →